Publication: Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A clinical trial
Issued Date
2018-07-01
Resource Type
ISSN
23742445
23742437
23742437
Other identifier(s)
2-s2.0-85050538909
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
JAMA Oncology. Vol.4, No.7 (2018), 977-984
Suggested Citation
Melanie Royce, Thomas Bachelot, Cristian Villanueva, Mustafa Özgüroglu, Sergio J. Azevedo, Felipe Melo Cruz, Marc Debled, Roberto Hegg, Tatsuya Toyama, Carla Falkson, Joon Jeong, Vichien Srimuninnimit, William J. Gradishar, Christina Arce, Antonia Ridolfi, Chinjune Lin, Fatima Cardoso Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A clinical trial. JAMA Oncology. Vol.4, No.7 (2018), 977-984. doi:10.1001/jamaoncol.2018.0060 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45128
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A clinical trial
Other Contributor(s)
Champalimaud Foundation
Yonsei University Health System
University of New Mexico
Istanbul Üniversitesi
Centre Hospitalier Universitaire de Besancon
The University of Alabama at Birmingham
Le Centre Régional de Lutte Contre le Cancer Léon Bérard
Hospital de Clinicas de Porto Alegre
Novartis Pharma S.A.S.
Northwestern University Feinberg School of Medicine
Faculty of Medicine, Siriraj Hospital, Mahidol University
Universidade de Sao Paulo - USP
Institut Bergonie
Nagoya University
Novartis Pharmaceuticals Corporation
Instituto Brasileiro de Controle do Câncer
Yonsei University Health System
University of New Mexico
Istanbul Üniversitesi
Centre Hospitalier Universitaire de Besancon
The University of Alabama at Birmingham
Le Centre Régional de Lutte Contre le Cancer Léon Bérard
Hospital de Clinicas de Porto Alegre
Novartis Pharma S.A.S.
Northwestern University Feinberg School of Medicine
Faculty of Medicine, Siriraj Hospital, Mahidol University
Universidade de Sao Paulo - USP
Institut Bergonie
Nagoya University
Novartis Pharmaceuticals Corporation
Instituto Brasileiro de Controle do Câncer
Abstract
© 2018 American Medical Association. IMPORTANCE Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer. OBJECTIVE To investigate the combination of everolimus plus endocrine therapy in first-line and second-line treatment settings for postmenopausal women with estrogen receptor-positive, human epidermal growth receptor 2-negative advanced breast cancer. DESIGN, SETTING, AND PARTICIPANTS In the multicenter, open-label, single-arm, phase 2 BOLERO-4 (Breast Cancer Trials of Oral Everolimus) clinical trial, 245 patients were screened for eligibility; 202 were enrolled between March 7, 2013, and December 17, 2014. A median follow-up of 29.5 months had been achieved by the data cutoff date (December 17, 2016). INTERVENTIONS Patients received first-line treatment with everolimus, 10mg/d, plus letrozole, 2.5mg/d. Second-line treatment with everolimus, 10mg/d, plus exemestane, 25 mg/d, was offered at the investigator's discretion upon initial disease progression. MAIN OUTCOMES AND MEASURES The primary end pointwas investigator-assessed progression-free survival in the first-line setting per Response Evaluation Criteria in Solid Tumors, version 1.0. Safety was assessed in patients who received at least 1 dose of study medication and at least 1 postbaseline safety assessment. RESULTS A total of 202 women treated in the first-line setting had a median age of 64.0 years (interquartile range, 58.0-70.0 years) with metastatic (194 [96.0%]) or locally advanced (8 [4.0%]) breast cancer. Median progression-free survival was 22.0 months (95%CI, 18.1-25.1 months) with everolimus and letrozole. Median overall survival was not reached; 24-month estimated overall survival rate was 78.7%(95%CI, 72.1%-83.9%). Fifty patients started second-line treatment; median progression-free survival was 3.7 months (95%CI, 1.9-7.4 months). No new safety signals were observed. In the first-line setting, the most common all-grade adverse event was stomatitis (139 [68.8%]); the most common grade 3 to 4 adverse event was anemia (21 [10.4%]). In the second-line setting, the most common adverse events were stomatitis and decreased weight (10 [20.0%] each); the most common grade 3 to 4 adverse event was hypertension (5 [10.0%]). There were 50 (24.8%) deaths overall during the study; 40 were due to study indication (breast cancer). CONCLUSIONS AND RELEVANCE The results of this trial add to the existing body of evidence suggesting that everolimus plus endocrine therapy is a good first-line treatment option for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.